Compare RJF & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJF | NTRA |
|---|---|---|
| Founded | 1962 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5B | 27.0B |
| IPO Year | N/A | 2015 |
| Metric | RJF | NTRA |
|---|---|---|
| Price | $170.76 | $242.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $182.91 | ★ $249.53 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 01-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 6.19 | N/A |
| EPS | ★ 10.30 | N/A |
| Revenue | ★ $14,015,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | $14.72 | $33.42 |
| Revenue Next Year | $5.60 | $16.96 |
| P/E Ratio | $16.51 | ★ N/A |
| Revenue Growth | 9.52 | ★ 38.17 |
| 52 Week Low | $117.57 | $125.38 |
| 52 Week High | $177.66 | $256.36 |
| Indicator | RJF | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 57.64 |
| Support Level | $165.41 | $226.66 |
| Resistance Level | $174.70 | $243.03 |
| Average True Range (ATR) | 4.32 | 9.85 |
| MACD | 0.18 | -0.59 |
| Stochastic Oscillator | 71.05 | 56.59 |
Raymond James Financial is a diversified financial services firm that provides wealth management, investment banking, asset management, and capital markets services to individuals, corporations, and municipalities. The firm maintains an extensive catalogue of products and services across its business lines. However, the wealth management franchise generates the bulk of its revenues and earnings through a vast network of nearly 8,800 independent and employee-affiliated advisors, who collectively manage over $1.7 trillion in client assets as of fiscal year-end 2025. While Raymond James maintains a global footprint, the company derives over 90% of its revenue, and an even larger percentage of its operating income, from the United States.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.